Literature DB >> 34191272

Correlation analysis of CT-based rectal planning dosimetric parameters with in vivo dosimetry of MOSkin and PTW 9112 detectors in Co-60 source HDR intracavitary cervix brachytherapy.

Z Jamalludin1,2,3, R A Malik2,3, N M Ung4,5.   

Abstract

Intracavitary cervical brachytherapy delivers high doses of radiation to the target tissue and a portion of these doses will also hit the rectal organs due to their close proximity. Rectal dose can be evaluated from dosimetric parameters in the treatment planning system (TPS) and in vivo (IV) dose measurement. This study analyzed the correlation between IV rectal dose with selected volume and point dose parameters from TPS. A total of 48 insertions were performed and IV dose was measured using the commercial PTW 9112 semiconductor diode probe. In 18 of 48 insertions, a single MOSkin detector was attached on the probe surface at 50 mm from the tip. Four rectal dosimetric parameters were retrospectively collected from TPS; (a) PTW 9112 diode maximum reported dose (RPmax) and MOSkin detector, (b) minimum dose to 2 cc (D2cc), (c) ICRU reference point (ICRUr), and (d) maximum dose from additional points (Rmax). The IV doses from both detectors were analyzed for correlation with these dosimetric parameters. This study found a significantly high correlation between IV measured dose from RPmax (r = 0.916) and MOSkin (r = 0.959) with TPS planned dose. The correlation between measured RPmax with both D2cc and Rmax revealed high correlation of r > 0.7, whereas moderate correlation (r = 0.525) was observed with ICRUr. There was no significant correlation between MOSkin IV measured dose with D2cc, ICRUr and Rmax. The non-significant correlation between parameters was ascribable to differences in both detector position within patients, and dosimetric volume and point location determined on TPS, rather than detector uncertainties.

Entities:  

Keywords:  Co-60 HDR brachytherapy; In vivo dosimetry; MOSkin; Rectal D2cc; Rectal ICRU

Year:  2021        PMID: 34191272     DOI: 10.1007/s13246-021-01026-x

Source DB:  PubMed          Journal:  Phys Eng Sci Med        ISSN: 2662-4729


  13 in total

1.  Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy.

Authors:  R Pötter; E Van Limbergen; N Gerstner; A Wambersie
Journal:  Radiother Oncol       Date:  2001-01       Impact factor: 6.280

2.  In-vivo dosimetry for gynaecological brachytherapy: physical and clinical considerations.

Authors:  Claudia Waldhäusl; André Wambersie; Richard Pötter; Dietmar Georg
Journal:  Radiother Oncol       Date:  2005-10-14       Impact factor: 6.280

3.  Computed tomography-based high-dose-rate intracavitary brachytherapy for uterine cervical cancer: preliminary demonstration of correlation between dose-volume parameters and rectal mucosal changes observed by flexible sigmoidoscopy.

Authors:  Woong Sub Koom; Dae Kyung Sohn; Joo-Young Kim; Jong Won Kim; Kyung Hwan Shin; Sang Min Yoon; Dae Yong Kim; Myonggeun Yoon; Dongho Shin; Sung Yong Park; Kwan Ho Cho
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-07       Impact factor: 7.038

4.  Semiconductor real-time quality assurance dosimetry in brachytherapy.

Authors:  Mauro Carrara; Dean Cutajar; Saree Alnaghy; Anthony Espinoza; Anna Romanyukha; Stefano Presilla; Chiara Tenconi; Annamaria Cerrotta; Carlo Fallai; Mitra Safavi-Naeini; Marco Petasecca; Alannah Kejda; Michael Lerch; Stéphanie Corde; Michael Jackson; Andrew Howie; Joseph Bucci; Anatoly B Rosenfeld
Journal:  Brachytherapy       Date:  2017-09-28       Impact factor: 2.362

5.  In vivo diode dosimetry vs. computerized tomography and digitally reconstructed radiographs for critical organ dose calculation in high-dose-rate brachytherapy of cervical cancer.

Authors:  Ashraf H Hassouna; Yasir A Bahadur; Camelia Constantinescu; Mohamed E El Sayed; Hussain Naseem; Adly F Naga
Journal:  Brachytherapy       Date:  2011-06-02       Impact factor: 2.362

6.  Late rectal complication following high dose rate intracavitary brachytherapy in cancer of the cervix.

Authors:  I Ogino; T Kitamura; N Okamoto; K Yamasita; Y Aikawa; H Okajima; S Matsubara
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-02-15       Impact factor: 7.038

7.  Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study.

Authors:  Kathrin Kirchheiner; Remi A Nout; Jacob C Lindegaard; Christine Haie-Meder; Umesh Mahantshetty; Barbara Segedin; Ina M Jürgenliemk-Schulz; Peter J Hoskin; Bhavana Rai; Wolfgang Dörr; Christian Kirisits; Søren M Bentzen; Richard Pötter; Kari Tanderup
Journal:  Radiother Oncol       Date:  2016-01-09       Impact factor: 6.280

8.  In vivo dosimetry with semiconductors in medium dose rate (MDR) brachytherapy for cervical cancer.

Authors:  Mahmoud Allahverdi; Ramin Jaberi; Mehdi Aghili; Fatemeh Ghahremani; Ghazale Geraily
Journal:  Jpn J Radiol       Date:  2012-12-05       Impact factor: 2.374

9.  Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.

Authors:  Richard Pötter; Johannes Dimopoulos; Petra Georg; Stefan Lang; Claudia Waldhäusl; Natascha Wachter-Gerstner; Hajo Weitmann; Alexander Reinthaller; Tomas Hendrik Knocke; Stefan Wachter; Christian Kirisits
Journal:  Radiother Oncol       Date:  2007-05       Impact factor: 6.280

10.  Correlation of dose-volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy.

Authors:  Petra Georg; Christian Kirisits; Gregor Goldner; Wolfgang Dörr; Johann Hammer; Regina Pötzi; Daniel Berger; Johannes Dimopoulos; Dietmar Georg; Richard Pötter
Journal:  Radiother Oncol       Date:  2009-02-23       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.